Has Sridhar Nambi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $86,000 in general payments to Sridhar Nambi, MD across 83 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sridhar Nambi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sridhar Nambi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sridhar Nambi, MD

Endocrinology, Diabetes & Metabolism · Livingston, NJNPI 1053388439

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $82,809 of the $86,000 with a category attached, or 96.3%. Novo Nordisk accounts for 97.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $29,755 and has fallen 89.6% since, to $3,080 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,000in general payments, 2019–2025

Across 83 payments — averaging $1036.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$84K
Medtronic$2K
Cequr Corporation$81
Mannkind Corporation$59
Abbott$33

What the payments were for

Speaking & faculty fees$82,80996%
Travel & lodging$6631%
Food & beverage$2,4693%
Gifts$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	65	$84,081
Medtronic(2 entities)	14	$1,746
Cequr Corporation	1	$81
Mannkind Corporation	1	$59
Abbott	2	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,000 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$163,175

Medicare patients

522

Services billed

1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	206	$391,486
JardianceEmpagliflozin	113	$128,757
TrulicityDulaglutide	67	$107,307
RybelsusSemaglutide	53	$97,602
FarxigaDapagliflozin Propanediol	64	$96,993
JanuviaSitagliptin Phosphate	82	$73,606
Xultophy 100-3.6Insulin Degludec/Liraglutide	26	$72,820
MounjaroTirzepatide	33	$55,124
Humalog Kwikpen U-100Insulin Lispro	110	$39,821
Tresiba Flextouch U-200Insulin Degludec	19	$30,208
Bydureon BciseExenatide Microspheres	13	$30,091
Soliqua 100-33Insulin Glargine/Lixisenatide	21	$29,088
JanumetSitagliptin Phos/Metformin Hcl	17	$24,208
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	40	$22,393
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	110	$20,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6	$84,081	$561,908285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Livingston

Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Navtika DesaiHillsborough$408K
Taher ModarressiPennington$402K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K
Stanislav GoykhmanLyndhurst$278K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →